ERBB2 and lung carcinoma: In addition, our results supported previous findings on targeting amplification-associated dependencies in particular tumor types, such as ERBB2/HER2 in 17q12 amplified breast cancer, FGF19/FGF4 in 11q13 amplified liver cancer, or MET in 7q31 amplified lung cancer, and suggested its extension to other tumors.